THERAPY DOSSIER · th-77709cd21042

MRS2578 (P2Y6 receptor antagonist)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32154670 ↗2020Reported harm

P2Y6 receptor inhibition aggravates ischemic brain injury by reducing microglial phagocytosis.

MouseIschaemia-reperfusionCerebral (MCAO/stroke)ICRMalen = Sham n = 6, saline plus DMSO n = 15, MRS2578 n = 12; figure…Intraperitoneal3 mg/kg, prepared from a 10 mg/mL DMSO stock diluted in sal…First injection 3 hours after occlusion

Model: Transient middle cerebral artery occlusion for 90 minutes with a silicone-coated 6-0 monofilament followed by reperfusion under isoflurane anaesthesia

Blocking P2Y6 with MRS2578 reduced microglial phagocytosis and worsened outcome: infarct volume, brain atrophy, neurological severity score, foot fault ratio, weight loss and mortality all increased. Inflammatory cytokines and MPO were unchanged. The findings indicate that endogenous P2Y6-mediated…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…